Stonehage Fleming Financial Services Holdings Ltd Invests $1.28 Million in Edwards Lifesciences Corporation $EW

Stonehage Fleming Financial Services Holdings Ltd bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 14,152 shares of the medical research company’s stock, valued at approximately $1,280,000.

Several other institutional investors also recently bought and sold shares of the stock. TrinityBridge Ltd purchased a new stake in Edwards Lifesciences in the 2nd quarter worth approximately $27,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $26,000. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences during the 1st quarter valued at approximately $25,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $27,000. Finally, JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,857 shares of company stock worth $170,305 over the last ninety days. 0.31% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

EW has been the topic of several analyst reports. Mizuho raised their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Truist Financial upped their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. UBS Group began coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price on the stock. Piper Sandler restated an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Finally, JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Stock Down 0.9%

Shares of NYSE EW opened at $89.97 on Friday. The firm has a market cap of $51.81 billion, a price-to-earnings ratio of 51.71, a price-to-earnings-growth ratio of 2.38 and a beta of 0.85. The company’s 50-day simple moving average is $89.48 and its 200-day simple moving average is $84.99. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.